{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:15:27Z","timestamp":1740158127056,"version":"3.37.3"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016796","name":"Adaptive Biotechnologies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016796","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clml.2024.09.014","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T20:25:44Z","timestamp":1728505544000},"page":"188-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7986-4826","authenticated-orcid":false,"given":"Julie E.","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"McQuinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2285-4026","authenticated-orcid":false,"given":"Meredith","family":"Hyun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KyungMann","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4539-9332","authenticated-orcid":false,"given":"Vaishalee P.","family":"Kenkre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saurabh A.","family":"Rajguru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka A.","family":"Pophali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariah","family":"Endres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitch","family":"Howard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Wassenaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth Callaway","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan J.","family":"Mattison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari B.","family":"Wisinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.09.014_bib0001","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jgo.2017.12.001","article-title":"Treatment of mantle cell lymphoma in older adults","volume":"9","author":"Pease","year":"2018","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.clml.2024.09.014_bib0002","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1080\/10428194.2019.1605511","article-title":"Mantle cell lymphoma: therapeutic options in transplant-ineligible patients","volume":"60","author":"Robak","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.09.014_bib0003","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2024.09.014_bib0004","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.014_bib0005","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/blood-2022-170381","article-title":"Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) \u00b1 Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411","volume":"140","author":"Smith","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.014_bib0006","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1182\/bloodadvances.2019000526","article-title":"Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma","volume":"3","author":"Kamdar","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.09.014_bib0007","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.09.014_bib0008","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.09.014_bib0009","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3109\/10428194.2011.649476","article-title":"A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma","volume":"53","author":"Warsch","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.09.014_bib0010","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1093\/annonc\/mdv364","article-title":"Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"26","author":"Graf","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2024.09.014_bib0011","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.09.014_bib0012","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with Mantle Cell Lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly Trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.09.014_bib0013","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2016.34.15_suppl.7503","volume":"34","author":"Rummel","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.09.014_bib0014","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2141.2011.08820.x","article-title":"VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study","volume":"155","author":"Chang","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.09.014_bib0015","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood.V114.22.1704.1704","article-title":"Phase I study of RO5072759 (GA101) in patients with relapsed\/refractory CD20+ Non-Hodgkin Lymphoma (NHL)","volume":"114","author":"Salles","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.014_bib0016","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.09.014_bib0017","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1517\/14712598.2012.657622","article-title":"Obinutuzumab for the treatment of lymphoproliferative disorders","volume":"12","author":"Owen","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clml.2024.09.014_bib0018","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.014_bib0019","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.2010.08428.x","article-title":"Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells","volume":"152","author":"Patz","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.09.014_bib0020","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/1535-7163.MCT-10-0385","article-title":"Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101","volume":"10","author":"Dalle","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2024.09.014_bib0021","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.09.014_bib0022","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbmt.2015.08.035","article-title":"Pretransplantation minimal residual disease predicts survival in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in complete remission","volume":"22","author":"Cowan","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2024.09.014_bib0023","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.014_bib0024","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3324\/haematol.2011.050203","article-title":"Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909","volume":"97","author":"Liu","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.09.014_bib0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.seminhematol.2011.05.002","article-title":"Minimal residual disease detection in mantle cell lymphoma: technical aspects and clinical relevance","volume":"48","author":"Pott","year":"2011","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2024.09.014_bib0026","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.09.014_bib0027","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.09.014_bib0028","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.09.014_bib0029","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13045-020-00961-8","article-title":"Advances in the assessment of minimal residual disease in mantle cell lymphoma","volume":"13","author":"Jung","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2024.09.014_bib0030","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood.V114.22.405.405","volume":"114","author":"Rummel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.014_bib0031","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.09.014_bib0032","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood.2024023962","article-title":"Randomized study of induction with bendamustine-rituximab \u00b1 bortezomib and maintenance with rituximab \u00b1 lenalidomide for MCL","volume":"144","author":"Smith","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.014_bib0033","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.09.014_bib0034","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2352-3026(20)30291-X","article-title":"Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group","volume":"7","author":"Le Gouill","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.09.014_bib0035","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood-2023-180069","article-title":"A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-na\u00efve, TP53-mutant mantle cell lymphoma","volume":"142","author":"Kumar","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.014_bib0036","unstructured":"Network NCC. B-cell Lymphomas (version 2.2024). 2024."},{"key":"10.1016\/j.clml.2024.09.014_bib0037","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.014_bib0038","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/asheducation-2016.1.437","article-title":"Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment","volume":"2016","author":"Hoster","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2024.09.014_bib0039","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3324\/haematol.11267","article-title":"Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations","volume":"93","author":"Bottcher","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.09.014_bib0040","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3324\/haematol.2024.285845","article-title":"Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation","volume":"109","author":"Epstein-Peterson","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.09.014_bib0041","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/s41375-021-01241-1","article-title":"Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations","volume":"35","author":"Wierda","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.09.014_bib0042","doi-asserted-by":"crossref","first-page":"29944","DOI":"10.18632\/oncotarget.25714","article-title":"Tolerability of obinutuzumab therapy in patients with rituximab-relapsed\/refractory B-cell malignancies: a retrospective single center cohort study","volume":"9","author":"Pirich","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2024.09.014_bib0043","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/hon.2828","article-title":"Obinutuzumab-related adverse events: a systematic review and meta-analysis","volume":"39","author":"Amitai","year":"2021","journal-title":"Hematol Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T12:47:14Z","timestamp":1739364434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024023589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2152265024023589"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}